biostudies-literatureUnknown89(5)Romano LGR<h4>Aims</h4>Nadroparin is administered to COVID-19 intensive care unit (ICU) patients as thromboprophylaxis. Despite existing population pharmacokinetic (PK) models for nadroparin in literature, the population PK of nadroparin in COVID-19 ICU patients is unknown. Moreover, optimal dosing regimens achieving anti-Xa target levels (0.3-0.7 IU/mL) are unknown. Therefore, a population PK analysis was conducted to investigate different dosing regimens of nadroparin in COVID-19 ICU patients.<h4>Methods</h4>Anti-Xa levels (n = 280) from COVID-19 ICU patients (n = 65) receiving twice daily (BID) 5700 IU of subcutaneous nadroparin were collected to perform a population PK analysis with NONMEM v7.4.1. Using Monte Carlo simulations (n = 1000), predefined dosing regimens were evaluated.<h4>Results</h4British journal of clinical pharmacology1617-1628https://www.ebi.ac.uk/biostudies/studies/S-EPMC9878197biostudies-literaturePopulation pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.PMC9878197Endeman HRomano LGRHunfeld NGMKruip MJHAPreijers TfalsePopulation pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.<h4>Aims</h4>Nadroparin is administered to COVID-19 intensive care unit (ICU) patients as thromboprophylaxis. Despite existing population pharmacokinetic (PK) models for nadroparin in literature, the population PK of nadroparin in COVID-19 ICU patients is unknown. Moreover, optimal dosing regimens achieving anti-Xa target levels (0.3-0.7 IU/mL) are unknown. Therefore, a population PK analysis was conducted to investigate different dosing regimens of nadroparin in COVID-19 ICU patients.<h4>Methods</h4>Anti-Xa levels (n = 280) from COVID-19 ICU patients (n = 65) receiving twice daily (BID) 5700 IU of subcutaneous nadroparin were collected to perform a population PK analysis with NONMEM v7.4.1. Using Monte Carlo simulations (n = 1000), predefined dosing regimens were evaluated.<h4>Results</h42023-01-01T00:00:00Z2023 May2025-04-18T14:06:06.694Z2025-04-06T23:59:56.451ZS-EPMC98781973649531210.1111/bcp.15634